Class of 2024
For visionary contributions to the clinical development of several cancer medicines, including ipilimumab, the first immune checkpoint inhibitor; nivolumab, the first PD1 inhibitor in multiple indications; olaparib, the first PARP inhibitor; osimertinib for lung cancer; durvalumab for multiple cancers; tremelimumab for lung and hepatocellular cancers; savolitinib for lung cancer; acalabrutinib for chronic lymphocytic leukemia, and capivasertib for breast cancer.
*Full-length biography pending